Abstract: An indoline compound. Specifically disclosed is an application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.

Abstract: A salt form of a tetra-substituted olefin compound, a crystal of the compound and the salt, and a preparation method relating to a crystal of a compound represented by formula (I), a salt thereof, a crystal of the salt thereof, and a preparation method therefor.

Abstract: The present application relates to a novel conjugate group linkable to a compound (such as a therapeutic compound), for use in directing the compound to a target in the body. The conjugate group disclosed herein can enable an expression-inhibitory oligonucleotide (such as a RNAi reagent) to target liver cells to regulate gene expression. The conjugate group disclosed herein has a variety of applications when linked to expression-inhibitory oligonucleotides, comprising applications in therapy, diagnosis, target verification, and genome development. A composition comprising the conjugate group disclosed herein can mediate expression of target nucleic acid sequences in liver cells (such as hepatocytes) when linked to expression-inhibitory oligonucleotides, and can be used for treatment of diseases or disorders responding to the gene expression or activity of cells, tissues, or organisms.

Abstract: Disclosed are a salt form used as a CDC7 inhibitor and a crystal form thereof, and specifically disclosed is a compound represented by formula (II), a crystal form thereof, a preparation method thereof, and an application thereof in the preparation of a drug for preventing or treating tumors.

Abstract: Disclosed is a crystal form of a hepatitis B surface antigen inhibitor and a preparation method, and an application of the crystal form in the preparation of the hepatitis B surface antigen inhibitor.

Abstract: Provided is an isochroman compound represented by formula (I), or a pharmaceutically acceptable salt thereof, which is used as an aldo-keto reductase (AKR1C3) inhibitor for the treatment of liver cancer.

Abstract: Disclosed is a type of indolo heptamyl oxime analog crystalline form as a PARP inhibitor and a method for preparing the same, specifically relating to a crystalline form of a compound of formula (I) and a method for preparing the same.

Abstract: A pyrimidine ring compound represented by formula (III), or a pharmaceutically acceptable salt thereof, and an application thereof in preparation of a medication for treating related diseases.

Abstract: Disclosed are a crystalline form of a Toll-like receptor 8 (TLR8) agonist as represented by formula (I) and a preparation method therefor. Further provided is an application of the crystalline form in the preparation of a drug for treating a disease responsive to the TLR8 agonist.

Abstract: A quinazoline compound and a pharmaceutically acceptable salt thereof, in particular a compound of formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.

Abstract: Provided are a double-stranded siRNA analogue embedded with a ribavirin derivative, a conjugate containing same, and a salt and the use thereof. The provided double-stranded siRNA analogue, the conjugate containing same and the salt thereof can effectively inhibit multiple viral indicators such as hepatitis B virus DNA, pgRNA, S antigen, and E antigen, which provide an effective and feasible method for treating hepatitis B.

Abstract: Provided is an application of a ribavirin derivative as an oligonucleotide embedded group. Specifically, disclosed is an application of r as a siRNA embedded group. Also provided is an r?-embedded siRNA conjugate, a double-stranded siRNA conjugate, a salt thereof, and an application thereof. The r?-embedded siRNA conjugate and the salt thereof can effectively reduce the S antigen content and E antigen content of the hepatitis B virus, providing an effective, feasible approach for the functional cure of chronic hepatitis B.

Abstract: The present application relates to a novel conjugate group linkable to a compound (such as a therapeutic compound), for use in directing the compound to a target in the body. The conjugate group disclosed herein can enable an expression-inhibitory oligonucleotide (such as a RNAi reagent) to target liver cells to regulate gene expression. The conjugate group disclosed herein has a variety of applications when linked to expression-inhibitory oligonucleotides, comprising applications in therapy, diagnosis, target verification, and genome development. A composition comprising the conjugate group disclosed herein can mediate expression of target nucleic acid sequences in liver cells (such as hepatocytes) when linked to expression-inhibitory oligonucleotides, and can be used for treatment of diseases or disorders responding to the gene expression or activity of cells, tissues, or organisms.

Abstract: Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Specifically, disclosed are a compound represented by formula (I) and a pharmacologically acceptable salt thereof.

Abstract: The present invention relates to a combination of a compound represented by formula (I) and other drugs for treating hepatitis B that is used for treating hepatitis B, and use of the combination in the preparation of drugs for treating hepatitis B.

Abstract: Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.

Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a salt type and a crystal form (I) of a diazaspiropyran compound, and a preparation method therefor. Also disclosed is the use of the salt type and the crystal form in the preparation of drugs for treating related diseases.

Abstract: Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor.